MedTrace Logo

Sotorasib in Advanced KRASG12C-mutated Non-small Cell Lung Cancer Patients With Comorbidities

NCT05311709 · Status: RECRUITING · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 100

Last updated 2023-11-09

No results posted yet for this study

Summary

A single-arm, multicentre trial to investigate sotorasib in KRASG12C-mutated non-small cell lung cancer stage III/IV not amenable for curative treatment including patients with comorbidities, and to provide translational knowledge regarding mechanism of relapse and differences in responses, including differences among patients with different co-occurring mutations.

Conditions

  • Lung Cancer
  • NSCLC, Stage III
  • NSCLC Stage IV
  • Lung Cancer Stage IV
  • Mutation
  • Cancer
  • Cancer, Lung

Interventions

DRUG

sotorasib

single group, all patients receive sotorasib

Sponsors & Collaborators

  • Aarhus University Hospital

    collaborator OTHER

  • Oslo University Hospital

    collaborator OTHER

  • Rigshospitalet, Denmark

    collaborator OTHER

  • Odense University Hospital

    collaborator OTHER

  • Karolinska University Hospital

    collaborator OTHER

  • University Hospital of North Norway

    collaborator OTHER

  • Haukeland University Hospital

    collaborator OTHER

  • St. Olavs Hospital

    collaborator OTHER

  • Vestre Viken Hospital Trust

    lead OTHER

Principal Investigators

  • Odd Terje Brustugun, MD, PhD · Vestre Viken Health trust

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2022-05-30
Primary Completion
2024-10-01
Completion
2025-03-01

Countries

  • Norway

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05311709 on ClinicalTrials.gov